Observational studyJCO precision oncology2021
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
Observational study in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03061305 (An Observational Trial Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Observational Trial Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Who cites it
20 citing papers in PubMed.
- Liquid biopsy: a new window on the BRCA genes.ESMO open · 2026Review
- Real-World Implementation of Next-Generation Sequencing in Sarcoma: Molecular Insights and Therapeutic Outcomes.Medical sciences (Basel, Switzerland) · 2026Article
- From Radical Resection to Precision Surgery: Integrating Diagnostic Biomarkers, Radiomics-Based Predictive Models, and Perioperative Systemic Therapy in Head and Neck Oncology.Diagnostics (Basel, Switzerland) · 2025Review
- Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study.The oncologist · 2025Observational
- Development and Application of MiMouse, a Comprehensive Genomic Profiling Panel for Credentialing Mouse Tumor Models.Cancer research communications · 2025Article
- Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling.The journal of liquid biopsy · 2025Article
- Patient and physician preferences for cancer panel testing in Japan: a best-worst scaling study.BMJ open · 2025Observational
- Successful surgical management of a patient with osteoradionecrosis of the jaw with RET fusion-positive advanced thyroid cancer: A case report.Experimental and therapeutic medicine · 2025Article
- Molecular Biological Determination ofInternational journal of molecular sciences · 2025Article
- Oil blotting paper for formalin fixation increases endoscopic ultrasound-guided tissue acquisition-collected sample volumes on glass slides.Cancer medicine · 2024Article
- Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer.JCO precision oncology · 2024Article
- Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.Nature cancer · 2024Article
- Article
- Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.EClinicalMedicine · 2023Article
- Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.Current oncology (Toronto, Ont.) · 2023Article
- Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.Communications medicine · 2023Article
- Toward a More Just System of Care in Molecular Pathology.The Milbank quarterly · 2022Article
- An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.The oncologist · 2022Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors.
Funding
Abstract
purposeTissue-based comprehensive genomic profiling (CGP) is increasingly used for treatment selection in patients with advanced cancer; however, tissue availability may limit widespread implementation. Here, we established real-world CGP tissue availability and assessed CGP performance on consecutively received samples. MATERIALS AND
methodsWe conducted a post hoc, nonprespecified analysis of 32,048 consecutive tumor tissue samples received for StrataNGS, a multiplex polymerase chain reaction (PCR)-based comprehensive genomic profiling (PCR-CGP) test, as part of an ongoing observational trial (NCT03061305). Sample characteristics and PCR-CGP performance were assessed across all tested samples, including exception samples not meeting minimum input quality control (QC) requirements (< 20% tumor content [TC], < 2 mm
resultsAmong 31,165 (97.2%) samples where PCR-CGP was attempted, 10.7% had < 20% TC and 59.2% were small (< 25 mm
conclusionMost real-world tissue samples from patients with advanced cancer desiring CGP are limited, requiring optimized CGP approaches to produce meaningful results. An optimized PCR-CGP test, coupled with an inclusive exception testing policy, delivered reportable results for > 94% of samples, potentially expanding the proportion of CGP-testable patients and impact of biomarker-guided therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.